Literature DB >> 10048585

Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells.

K Mishra-Gorur1, J J Castellot.   

Abstract

Aberrant vascular smooth muscle cell (VSMC) hyperplasia is the hallmark of atherosclerosis and restenosis seen after vascular surgery. Heparin inhibits VSMC proliferation in animal models and in cell culture. To test our hypothesis that heparin mediates its antiproliferative effect by altering phosphorylation of key mitogenic signaling proteins in VSMC, we examined tyrosine phosphorylation of cellular proteins in quiescent VSMC stimulated with serum in the presence or absence of heparin. Western blot analysis with anti-phosphotyrosine antibodies shows that heparin specifically alters the tyrosine phosphorylation of only two proteins (42 kDa and 200 kDa). The 200 kDa protein (p200) is dephosphorylated within 2.5 min after heparin treatment with an IC50 that closely parallels the IC50 for growth inhibition. Studies using the tyrosine phosphatase inhibitor, sodium orthovanadate, indicate that heparin blocks p200 phosphorylation by inhibiting a kinase. Phosphorylation of p200 is not altered in heparin-resistant cells, supporting a role for p200 in mediating the antiproliferative effect of heparin. Purification and sequence analysis indicate that p200 exhibits very high homology to the heavy chain of nonmuscle myosin IIA. The 42 kDa protein, identified as mitogen activated protein kinase (MAPK), undergoes dephosphorylation within 15 min after heparin treatment, and this effect is also not seen in heparin-resistant cells. The identification of only two heparin-regulated tyrosine phosphoproteins suggests that they may be key mediators of the antiproliferative effect of heparin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048585     DOI: 10.1002/(SICI)1097-4652(199902)178:2<205::AID-JCP10>3.0.CO;2-9

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Heparin stimulates elastogenesis: application to silk-based vascular grafts.

Authors:  Cassandra Saitow; David L Kaplan; John J Castellot
Journal:  Matrix Biol       Date:  2011-05-11       Impact factor: 11.583

2.  Heparin inhibits phosphorylation and autonomous activity of Ca(2+)/calmodulin-dependent protein kinase II in vascular smooth muscle cells.

Authors:  Ketu Mishra-Gorur; Harold A Singer; John J Castellot
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Effects of heparin on the production of homocysteine-induced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells.

Authors:  Hangyuan Guo; Jong-Dae Lee; Hiroyasu Uzui; Hong Yue; Ping Wang; Kiyohiro Toyoda; Tooru Geshi; Takanori Ueda
Journal:  Can J Cardiol       Date:  2007-03-15       Impact factor: 5.223

Review 4.  Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.

Authors:  J Marc Simard; David Schreibman; E Francois Aldrich; Bernadette Stallmeyer; Brian Le; Robert F James; Narlin Beaty
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

Review 5.  Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Norihito Shimamura; Hiroki Ohkuma
Journal:  Transl Stroke Res       Date:  2013-11-20       Impact factor: 6.829

6.  Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells.

Authors:  Holly R Mason; Romana A Nowak; Cynthia C Morton; John J Castellot
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

7.  Culture Medium Supplements Derived from Human Platelet and Plasma: Cell Commitment and Proliferation Support.

Authors:  Anita Muraglia; Van Thi Nguyen; Marta Nardini; Massimo Mogni; Domenico Coviello; Beatrice Dozin; Paolo Strada; Ilaria Baldelli; Matteo Formica; Ranieri Cancedda; Maddalena Mastrogiacomo
Journal:  Front Bioeng Biotechnol       Date:  2017-11-20

8.  Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning.

Authors:  Milka Janjic; Foteini Pappa; Varvara Karagkiozaki; Christakis Gitas; Kiriakos Ktenidis; Stergios Logothetidis
Journal:  Int J Nanomedicine       Date:  2017-08-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.